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Glomerulonephritis is responsible for over one 
half of all cases of end-stage chronic renal failure 
and, in its most fulminant form, is a cause of acute, 
irreversible renal failure. Electron microscopy and 
immunofluorescent studies together with newly rec-
ognized clinical associations have revealed a wide 
variety of histologic subgroups and myriad etiologies 
for what was once regarded as a single, simple entity. 
The addition of electron microscopy has lent an en-
tirely new dimension to the delineation of glomerulo-
nephritis subtypes and offers a more reasonable ap-
proach to the search for treatment of these subtypes. 
It is, after all, not unreasonable to suppose that dif-
ferent etiologic factors and host responses are in-
volved in the various pathologic lesions so clearly 
defined on electron microscopy. Immunofluorescent 
studies identify the presence of immune globulins and 
complement components in glomerular lesions and 
aid in recognition of their localization sites; they may 
reveal the contribution of fibrin deposition or specific 
antigens in the pathogenesis of glomerular in-
volvement. 
Most, if not all, forms of glomerulonephritis are 
acknowledged to be the result of immunologic proc-
esses, and many can be mimicked by immunologic 
manipulations in laboratory animals. A growing 
body of research data . has incriminated circulating 
immune complexes, activation of the complement 
cascade and the coagulation system, antibodies di-
rected specifically against the glomerular basement 
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membrane, proteolytic activity of leukocytes, and 
other phenomena in the mediation of particular types 
of glomerular injury. In experimental animals, at 
least, manipulation of the antigen: antibody ratio or 
depletion of complement and/ or polynuclear leuko-
cytes may blunt the severity of, or prevent entirely, 
lesions which are otherwise inevitable and severe. In 
the rabbit, the prophylactic administration of anti-
coagulants has marked beneficial effects on the devel-
opment of glomerulopathy. Unfortunately, com-
parable benefit is not observed when these maneuvers 
are performed after glomerular abnormalities are al-
ready established. 
Most experimentally induced glomerulopathies 
are self-limiting and of brief duration. Aside from the 
maneuvers mentioned in the previous paragraph, 
therapy which would be considered suitable for use in 
man appears for the most part to be of little benefit in 
the laboratory. In man, the value of currently avail-
able treatments intended to halt or reverse the pro-
gression of glomerular abnormalities is no more im-
pressive. Corticosteroids, immunosuppressive agents, 
and anticoagulants are of proven value in only a 
minority of histologically specific lesions (for ex-
ample, hypersensitivity angiitis, Wegener gran-
ulomatosis, minimal lesion nephrotic syndrome), and 
their efficacy in other forms of glomerulonephritis is 
strongly debated. The very existence of such debate, 
over 25 years after the introduction of steroid therapy 
and 15 years after azathioprine (Imuran) became 
available, should indicate that current treatment 
modes are less than optimally effective. New forms of 
treatment must be developed. 
Working on the assumption that immunologic 
mechanisms are the key to the appearance of glo-
merular injury, one would ideally search for new 
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means of turning off or minimizing the impact of 
those mechanisms, an approach which meets with 
considerable success in the prevention of renal trans-
plant rejection. Having been largely unsuccessful in 
achieving suitable manipulation of immune mecha-
nisms with our present knowledge, we can at least 
attempt to minimize the impact of the immune sys-
tem on the kidney. In that regard, a new approach to 
the problem is under study here at the Medical Col-
lege of Virginia and elsewhere-plasmapheresis. This 
technique involves the removal of the patient's 
plasma and replacing it with donor's plasma so as to 
remove circulating immune complexes and/or pre-
formed antikidney antibodies. Preliminary data in-
dicate that, in selected cases, significant improvement 
in renal function may follow such treatment. The 
overall value of plasmapheresis is still under review, 
however, and will not be known until suitable num-
bers of patients have received this treatment. 
Use of the "Melbourne cocktail"-a combina-
tion of dipyridamole, corticosteroid and heparin 
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therapy-has been reported to reverse the most ful-
minating and devastating form of acute glomerular 
disease termed "rapidly progressive glomerulone-
phritis." While the clinical presentation of oligoa-
nuria with virtually complete cessation of glomerular 
filtration in children is often completely reversible, it 
is rarely so in adults. Fibrin deposition, formation of 
luxuriant epithelial crescents, and marked cellular 
proliferation of the glomerular tuft typify this sub-
group of patients. Employing a treatment which af-
fects platelet aggregation and intracapillary coagu-
lation seems entirely rational but is not without 
hazard to the patient. Once this particular form of 
fulminating glomerulonephritis is recognized, how-
ever, the prognosis for return of renal function is so 
poor that the cocktail is being investigated in several 
centers. Evaluation of such treatment requires experi-
ence, ideal patient management and careful patient 
selection, and should be undertaken only under the 
most stringent precautions if we a re to establish its 
efficacy in a controlled fashion. 
